Biogen walks away from controversial Alzheimer’s drug Aduhelm
Pharmaceutical company Biogen announced Wednesday that it will relinquish ownership of its Alzheimer’s disease drug Aduhhelm, which sparked intense criticism of the company and the Food and Drug Administration (FDA) after it was approved in 2021. The company will also halt ongoing post-approval clinical trials ordered by the FDA to determine the drug’s effectiveness in […]